Долгая жизнь с муковисцидозом

335

Battezzati A, Battezzati PM, Costantini D, et al. Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol 2007; 156:369-76.

336

Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000; 162(3 Pt 1): 891-5.

337

Hameed S, Morton JR, Jaffe A, et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010;33:221-6.

338

Hunt WR, Zughaier SM, Guentert DE, et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 2014; 306: L43-9.

339

Lanng S, Thorsteinsson B, Nerup J, Koch С Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr1992; 151:684-7.

340

Dobson L, Sheldon CD, Hattersley AT. Understanding cysticfibrosis-re-lated diabetes: best thought of as insulin deficiency? J R Soc Med 2004;97 Suppl 44: 26–35.

341

Dobson L, Sheldon CD, Hattersley AT. Understanding cysticfibrosis-re-lated diabetes: best thought of as insulin deficiency? J R Soc Med 2004;97 Suppl 44: 26–35.

342

Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007; 30: 1056-61.

343

AdlerAI, Shine B, Haworth C, et al. Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care 2011; 34: 1577-8.

344

Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33: 2697-708.

345

Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33: 2697-708.

346

Waugh NR, Shyangdan D, Taylor-Phillips S, et al. Screening for type 2 diabetes: a short report for the National Screening Committee, Health Technol Assess 2013; 17:1-90

347

Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33: 2697-708.

348

Waugh N, Royle R Craigie I, et al. Screening for cystic fibrosis-related diabetes: a systematic review. Health Techno! Assess 2012; 16:iii-iv, 1-179.

349

Waugh N, Royle R Craigie I, et al. Screening for cystic fibrosis-related diabetes: a systematic review. Health Techno! Assess 2012; 16:iii-iv, 1-179.

350

Ode KL, Frohnert B, Laguna T, et al. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 2010; 11: 487-92.

351

Moran A, Pekow P, Grover Petal. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009; 32: 1783-8.

352

Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2013; 7: CD004730

353

Moran A, Phillips J, Milla С Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001; 24: 1706-10.

354

WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1994; 843: 1-129.

355

Bishop N, Arundel P, Clark E, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 2014; 17: 275-80

356

Haston CK, Li W, Li A, et al. Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am J Respir Crit Care Med 2008; 177:309-15.

357

Shead EF, Haworth CS, Condliffe AM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62: 650-1.

358

Shead EF, Haworth CS, Barker H, et al. Osteoclast function bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros2010;9:93-8.

359

Le Heron L, Guillaume C, Velard F, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerina (OPG) and prostaglandin (PG) E2 in human bone. J Cyst Fibros 2010; 9: 69–72.

360

King SJ, Topliss DJ, Kotsimbos T et al. Reduced bone density in cystic fibrosis: deltaF508 mutation is an independent risk factor. Eur Respir J 2005; 25: 54–61.

361

Bianchi ML, Romano G, Saraifoger S, et al. BMD and body composition in children and young patients affected by cystic fibrosis. J Bone Miner Res 2006; 21: 388-96.

362

Legroux-Gerot I, Leroy S, Prudhomme C, et al. Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers. Joint Bone Spine 2012; 79: 73-7.

363

Haworth CS, Impact of cystic fibrosis on bone health. Curr Opin Pulm Med 2010; 16:616-22.

364

Elkin SL, Fairney A, Burnett S, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int2001; 12:366-72.

365

Aris, RM, Merkel PA, Bachrach LK, et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90: 1888-96.

366

Paccou J, Zeboulon N, Combescure C, et al. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with metaanalysis. Calcif Tissue Int 2010; 86:1–7.

367

ArisRM, RennerJB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann intern Med 1998; 128:186-93.

368

Aris, RM, Merkel PA, Bachrach LK, et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90: 1888-96.

369

Conway SP, Oldroyd B, Brownlee KG, et al. A cross-sectional study of bone mineral density in children and adolescents attending a Cystic Fibrosis Centre. J Cyst Fibros 2008; 7: 469-76.

370

Kelly A, Schall Jl, Stallings VA, et al. Deficits in bone mineral content in children and adolescents with cystic fibrosis are related to height deficits. J Clin Densitom 2008; 11:581-9.

371

Buntain HM, Greer RM, Schluter PJ, et al. Bone mineral density in Australian children, adolescents, and adult with cystic fibrosis: a controlled cross sectional study. Thorax 2004; 59: 149-55.

372

Kelly A, Schall Jl, Stallings VA, et al. Deficits in bone mineral content in children and adolescents with cystic fibrosis are related to height deficits. J Clin Densitom 2008; 11:581-9.

373

Rovner AJ, Zemel BS, Leonard MB, et al. Mild to moderate cystic fibrosis is not associated with increased fracture risk in children and adolescents. J Pediatr 2005; 147:327-31.

374

Henderson RC, Specter BB. Kyphosis and fractures in children and young adults with cystic fibrosis. J Pediatr 1994; 125: 208-12.

375

SheikhS, Gemma S, Patel A. Factors associated with low bone mineral density in patients with cystic fibrosis. J Bone Miner Metab 2015; 33: 180-5

376

Schulze KJ, O'Brien КО, Germain-Lee EL, et al. Calcium kinetics are altered in clinically stable girls with cystic fibrosis. J Clin Endocrinol Metab 2004; 89: 3385-91.

377

Haworth CS, Seiby PL, Horrocks AW, et al. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 2002; 57: 719-23.

378

Sermet-Gaudelus I, Bianchi ML, Garabedian M, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011; 10(Suppl2):S16-23.

379

Hall WB, Sparks AA, Aris RM. Vitamin D deficiency in cystic fibrosis. Int J Endocrinol 2010: 2010:218691.

380

Hillman LS, Cassidy JT, Popescu MF, et al. Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic fibrosis: effect of supplementation with vitamin D and calcium. Pediatr Pulmonol 2008; 43: 772-80.

381

Ferguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst Rev2012;4:CD007298.

382

Green DM, Leonard AR, Paranjape SM, et al. Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. JCysFibros2010;9: 143-9.

383

Nicolaidou P, Stavrinadis I, Loukou I, et al. The effect of vitamin К supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur J Pediatr2006; 165:540-5.

384

Hind K, Truscott JG, Conway SP Exercise during childhood and adolescence: a prophylaxis against cystic fibrosis related low bone mineral density? Exercise for bone health in children with cystic fibrosis. J Cyst Fibros 2008; 7: 270-6.

385

Tejero Garcia S, Giraldes Sanchez MA, Cejudo P, et al. Bone health, daily physical activity, and exercise tolerance in patients with cystic fibrosis. Chest 2011; 140: 475-81.

386

Hardin DS, Adams-Huet B, Brown D, et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 2006; 91: 4925-9.

387

Arenas-de Larriva MS, Vaquero-Barrios JM, Redel-Montero J, et al. Bone mineral density in lung transplant candidates. Transpl Proc 2010; 42: 3208-10.

388

Aris, RM, Merkel PA, Bachrach LK, et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90: 1888-96.

389

Sermet-Gaudelus I, Bianchi ML, Garabedian M, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011; 10(Suppl2):S16-23.

390

Bianchi ML, Colombo C, Assael BM, et al. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respir Med 2013; 1:377-85.

391

Quon BS, Aitken ML. Cystic fibrosis: what to expect now in the early adult years. Paediatr Respir Rev 2012; 13:206-14.

392

Merkel PA. Rheumatic disease and cystic fibrosis. Arthritis Rheum 1999; 42: 1563-71.

393

Jayakar BA, Abelson AG, Yao Q. Treatment of hypertrophic osteoarthropathy with zoledronio acid: case report and review of the iterative. Semin Arthritis Rheum 2011;41:291-6.

394

Thornton J, Rangaraj S. Antiinflammatory drugs and analgesics for managing symptoms in people with cystic fibrosis-related arthritis. Cochrane Database Syst Rev 2012; 3: CD006838.

395

Sendzik J, Lode H, Stahlmann R, Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33: 194–200.

396

Andersen HO, Hjelt K, Waever E, et al. The age-related incidence of meconium ileus equivalent in a cystic fibrosis population: the impact of a high energy intake. J Pediatr Gastroenterol Nutr 1990; 11:355-60.

397

Dik H, Nicolai JJ, Schipper J, et al. Erroneous diagnosis of distal intestinal obstruction syndrome in cystic fibrosis: clinical impact of abdominal ultrasonography. Eur J Gastroenterol Hepatol 1995; 7: 27–81.

398

Colombo C, Ellemunter H, Houwen R, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cystic Fibros 2011; 10(Suppl 2): S24-S28.

399

Walkowiak J, Nousia-Arvanitakis S, Agguridaki C, etal. Longitudinal follow-up of exocrine pancreatic function in pancreatic sufficient cystic fibrosis patients using the fecal elastase-1 test. J Pediatr Gastroenterol Nutr 2003; 36: 474-8.

400

De Boeck K, Weren M, Proesmans M, et al. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics 2005; 115: e463-9.

401

Durno C, Corey M, Zielenski J, et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002; 123: 1857-64.

402

Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011; 140: 153-61.

403

Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011; 140: 153-61.

404

EsterlyJR, Oppenheimer EH. Observations in cystic fibrosis of the pancreas. I. The gallbladder. Bull Johns Hopkins Hosp 1962; 110: 247-55.

405

Modolell I, Alvarez A, Guarner L, et al. Gastrointestinal, liver, and pancreatic involvement in adult patients with cystic fibrosis. Pancreas 2001; 22: 395-9.

406

Bahmanyar S, Ekbom A, Askling J, et al. Cystic fibrosis gene mutations and gastrointestinal diseases. J Cyst Fibros 2010; 9: 288-91.

407

Bahmanyar S, Ekbom A, Askling J, et al. Cystic fibrosis gene mutations and gastrointestinal diseases. J Cyst Fibros 2010; 9: 288-91.

408

Colombo C, Bertolini E, Assaisso ML, et al. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993; 82: 562-5.

409

Cogliandolo A, Patania M, Curro G, et al. Postoperative outcomes and quality of life in patients with cystic fibrosis undergoing laparoscopic cholecystectomy: a retrospective study. Surg Laparosc Endosc Percutan Tech 2011; 21: 179-83.

410

Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999; 28(Suppl 1): S1-13.

411

Debray D, Kelly D, Houwen R, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011; 10(Suppl2):S29-36.

412

Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2014; 12:CD000222.

413

Rowland M, Gallagher C, Gallagher CG, et al. Outcome in patients with cystic fibrosis liver disease. J Cyst Fibros 2015; 14: 120-6.

414

Maisonneuve P, FitzSimmons SC, Neglia JP, et al. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003; 95: 381-7.

415

Maisonneuve P, Marshall ВС, Knapp EA, et al. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105: 122-9.

416

Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332: 494-9.

417

Neglia JRWielinski CL, Warwick WJ. Cancer risk among patients with cystic fibrosis. J Pediatr 1991; 119:764-6.

418

Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a metaanalysis. Eur J Cancer 2006; 42: 216-27.

419

France MW, Bell SC. Gastrointestinal malignancy in cystic fibrosis. CML Cystic Fibrosis 2014; 4: 1-14.

420

Dugue PA, Rebolj M, Garred R Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther 2013; 13: 29–42.

421

Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 263-79.

422

O'Connell OJ, McWilliams S, McGarrigle A, et al. Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades. Chest 2012; 141: 1575-83.

423

U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627-37.

424

Lieberman D. Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 2009; 25: 422-7.

425

Meyer КС, Francois ML, Thomas HK, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening. J Cyst Fibros 2011; 10:366-9.

426

Plant BJ, Goss CH, Plant WD, et al. Management of co-morbidities in older patients with cystic fibrosis. Lancet Respir Med 2013; 1: 164-74.

427

Salgia R, Singal AG. Hepatocellular carcinoma and other liver lesions. Med Clin North Am 2014; 98: 103-18.

428

OSullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891-904.

429

Belle-van Meerkerk G, Cramer MJ, Kwakkel-van Erp JM, et al. Pulmonary hypertension is a mild comorbidity in end-stage cystic fibrosis patients. J Heart Lung Transplant 2013; 32: 609-14.

430

Venuta F, Tonelli AR, Anile M, et al. Pulmonary hypertension is associated with higher mortality in cystic fibrosis patients awaiting lung transplantation. J Cardiovasc Surg 2012; 53: 817-20.

431

Bano-Rodrigo A, Salcedo-Posadas A, Villa-Asensi JR, et al. Right ventricular dysfunction in adolescents with mild cystic fibrosis. J Cyst Fibros 2012; 11: 274-80.

432

lonescu AA, lonescu AA, Payne N, et al. Subclinical right ventricular dysfunction in cystic fibrosis. A study using tissue Doppler echocardiography. Am J Respir Crit Care Med 2001; 163: 1212-8.

433

Koelling TM, Dec GW, Ginns LC, et al. Left ventricular diastolic function in patients with advanced cystic fibrosis. Chest 2003; 123: 1488-94.

434

Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32: 1626-31.

435

Cystic Fibrosis Australia 2012. 15th Annual Report from the Cystic Fibrosis Data Registry. Sydney: Cystic Fibrosis Australia; 2013.

436

Rhodes B, Nash Ep Tullis E, et al. Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibros 2010; 9: 24-8.

437

Coderre L, Fadainia C, Belson L, et al. LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients. J Cyst Fibros 2012; 11:393-7

438

Macnee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 824-33.

439

Hull JH, Garrod R, Но ТВ, et al. Increased augmentation index in patients with cystic fibrosis. Eur Respir J 2009; 34: 1322-8.

440

Hull JH, Garrod R, Но ТВ, et al. Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis. J Cyst Fibros 2013; 12: 125-9.

441

A-Rahman AK, Spencer D. Totally implantable vascular access devices for cystic fibrosis. Cochrane Database Syst Rev 2012; 5:CD004111.

442

Batacchi S, Zagli G, Braccini G, et al. Totally implantable vascular access devices in adult patients for cystic fibrosis management. Am J Respir Crit Care Med 2011; 183:133-4.

443

Dal Molin A, Di Massimo DS, Braggion C, et al. Totally implantable central venous access ports in patients with cystic fibrosis: a multicenter prospective cohort study. J Vase Access 2012; 13: 290-5.

444

Garwood S, Flume PA, Ravenel J. Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol 2006; 41: 683-7.

445

Smith D, Reid D, Slaughter R, et al. Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: case series and review. Respir Med CME 2011; 4: 99-104.

446

Smith D, Reid D, Slaughter R, et al. Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: case series and review. Respir Med CME 2011; 4: 99-104.

447

Balfour-Lynn IM, Malbon K, Burman JF et al. Thrombophilia in children with cystic fibrosis. Pediatr Pulmonol 2005; 39: 306-10.

448

Barker M, Thoenes D, Dohmen H, et al. Prevalence of thrombophilia and catheter-related thrombosis in cystic fibrosis. Pediatr Pulmonol 2005; 39: 156-61.

449

Williams V, Griffiths AB, Yap ZL, et al. Increased thrombophilic tendency in pediatric cystic fibrosis patients. Clin Appl Thromb Hemost2010; 16:71-6.

450

Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 1998; 20: 149-60.

451

JuskoWJ,MosvichLL, Gerbracht LM, et al. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 1974; 56: 1038-44.

452

Turvey S, Cronin B, Arnold A, et al. Dioun A. Antibiotic desensitization for the allergic patient: 5 years of experience and practice.

453

Peckham D, Whitaker P. Drug induced complications; can we do more? J Cyst Fibros 2013; 12: 547-58.

454

Hoffmann IM, Rubin BK, Iskandar SS, et al. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002; 34: 375-7.

455

Al-Aloul M, Miller H, Stockton P, et al. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 2005; 4:197–201.

456

Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39: 15–20.

457

Al-Aloul M, Miller H, Stockton P, et al. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 2005; 4:197–201.

458